Cargando…

PAK signaling in cancer

Transformation of a normal cell to a cancer cell is caused by mutations in genes that regulate proliferation, apoptosis, and invasion. Small GTPases such as Ras, Rho, Rac and Cdc42 orchestrate many of the signals that are required for malignant transformation. The p21-activated kinases (PAKs) are ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Diana Zi, Field, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490961/
https://www.ncbi.nlm.nih.gov/pubmed/23162742
http://dx.doi.org/10.4161/cl.21882
_version_ 1782248913042931712
author Ye, Diana Zi
Field, Jeffrey
author_facet Ye, Diana Zi
Field, Jeffrey
author_sort Ye, Diana Zi
collection PubMed
description Transformation of a normal cell to a cancer cell is caused by mutations in genes that regulate proliferation, apoptosis, and invasion. Small GTPases such as Ras, Rho, Rac and Cdc42 orchestrate many of the signals that are required for malignant transformation. The p21-activated kinases (PAKs) are effectors of Rac and Cdc42. PAKs are a family of serine/threonine protein kinases comprised of six isoforms (PAK1–6), and they play important roles in cytoskeletal dynamics, cell survival and proliferation. They act as key signal transducers in several cancer signaling pathways, including Ras, Raf, NFκB, Akt, Bad and p53. Although PAKs are not mutated in cancers, they are overexpressed, hyperactivated or amplified in several human tumors and their role in cell transformation make them attractive therapeutic targets. This review discusses the evidence that PAK is important for cell transformation and some key signaling pathways it regulates. This review primarily discusses Group I PAKs (PAK1, PAK2 and PAK3) as Group II PAKs (PAK4, PAK5 and PAK6) are discussed elsewhere in this issue (by Minden).
format Online
Article
Text
id pubmed-3490961
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34909612012-11-16 PAK signaling in cancer Ye, Diana Zi Field, Jeffrey Cell Logist Review Transformation of a normal cell to a cancer cell is caused by mutations in genes that regulate proliferation, apoptosis, and invasion. Small GTPases such as Ras, Rho, Rac and Cdc42 orchestrate many of the signals that are required for malignant transformation. The p21-activated kinases (PAKs) are effectors of Rac and Cdc42. PAKs are a family of serine/threonine protein kinases comprised of six isoforms (PAK1–6), and they play important roles in cytoskeletal dynamics, cell survival and proliferation. They act as key signal transducers in several cancer signaling pathways, including Ras, Raf, NFκB, Akt, Bad and p53. Although PAKs are not mutated in cancers, they are overexpressed, hyperactivated or amplified in several human tumors and their role in cell transformation make them attractive therapeutic targets. This review discusses the evidence that PAK is important for cell transformation and some key signaling pathways it regulates. This review primarily discusses Group I PAKs (PAK1, PAK2 and PAK3) as Group II PAKs (PAK4, PAK5 and PAK6) are discussed elsewhere in this issue (by Minden). Landes Bioscience 2012-04-01 /pmc/articles/PMC3490961/ /pubmed/23162742 http://dx.doi.org/10.4161/cl.21882 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Review
Ye, Diana Zi
Field, Jeffrey
PAK signaling in cancer
title PAK signaling in cancer
title_full PAK signaling in cancer
title_fullStr PAK signaling in cancer
title_full_unstemmed PAK signaling in cancer
title_short PAK signaling in cancer
title_sort pak signaling in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490961/
https://www.ncbi.nlm.nih.gov/pubmed/23162742
http://dx.doi.org/10.4161/cl.21882
work_keys_str_mv AT yedianazi paksignalingincancer
AT fieldjeffrey paksignalingincancer